Stain, an HMG-CoA reductase inhibitor which exerts significant effects in lowering cholesterin (TC) and low-density lipoprotein (LDL) levels, was found to exhibit protective effects against CRC by reducing the dilatation activity and enhancing the chemotherapeutic sensitivity of CRC cells (Bardou et al., 2010). The gene discussed is HMGCR; the disease is colorectal carcinoma.